Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-label, Dose-finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Axitinib (AG-013736) In Patients With Previously Untreated Advanced Renal Cell Cancer

Next Previous
Trial Profile

A Phase 1b, Open-label, Dose-finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Axitinib (AG-013736) In Patients With Previously Untreated Advanced Renal Cell Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Axitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms JAVELIN Renal 100
  • Sponsors Pfizer

    • Most Recent Events

    • 06 Jun 2023 Results of pooled exploratory analysis (n=2631 from four studies (KEYNOTE-426, JAVELIN Renal 100, CheckMate 9ER, CheckMate 214) assessing relationship of week 12 DepOR as a continuous variable with OS, hypothesizing not only complete but also deep partial responses might portend favorable longer-term survival in frontline advanced immuno-oncology renal cell carcinoma trials presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2023 Results of a pooled exploratory analysis assessing treatment free survival (TFS) with and without ongoing toxicity in addition to time on protocol therapy from three clinical trials: KEYNOTE-426, JAVELIN Renal 100 and CheckMate 9ER presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 06 Apr 2023 Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial assessing long-term safety and efficacy of avelumab plus axitinib as first-line treatment for patients with aRCC published in the Oncologist
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top